Lyell Immunopharma, Inc. (LYEL) · Nov 4, 2026 · Share issuance

Lyell Immunopharma private placement adds $80M but dilutes shareholders

$80M private placement — 7,428,040 shares at $10.77; approximately $80.0M gross proceeds

Lyell Immunopharma’s private placement raises $80 million for its CAR-T pipeline, but the funding comes with substantial share dilution.

Lyell is a late-stage clinical CAR-T company advancing ronde-cel through pivotal lymphoma trials and LYL273 through an expanded Phase 1/2 program in colorectal cancer. Before this filing, Lyell reported $228.0 million of cash, cash equivalents and marketable securities, with runway into the third quarter of 2027; the company also recently pushed additional LYL273 data and its FDA End-of-Phase 1 meeting into 2027.

The financing adds useful capital, but it is not a clinical advance. Lyell agreed to sell 7,428,040 shares at $10.77 each, with approximately $80.0 million of gross proceeds. That gives the company more resources to fund clinical development and manufacturing while it waits for 2027 milestones, but the filing does not provide a revised cash-runway estimate or say that the money funds a newly accelerated program.

Deal termsFigure
Shares issued (Purchase Agreement)7,428,040
Purchase price per share (Purchase Agreement)$10.77
Gross proceeds (Item 3.02)$80.0M
Latest reported shares outstanding (June 30, 2026)24.5M

The cost is substantial dilution. Against the latest reported 24.5 million shares outstanding, the new shares equal roughly 30% of the pre-financing share count, or about 23% of the enlarged base. That is meaningful for existing holders, especially because Lyell already said its cash position extended into Q3 2027; the financing improves flexibility more than it solves an immediate liquidity shortfall.

The transaction is effectively announced, not yet completed. Closing is scheduled for or about November 4, 2026, subject to customary conditions. The shares will initially carry restrictive legends, while Lyell must file a resale registration statement within 30 days after closing and can face cash penalties for registration failures. 〔0〕

Bottom line: This strengthens Lyell’s funding position for its clinical pipeline, but the benefit is tempered by dilution equal to roughly one-quarter of the post-financing share base. It is a modest funding positive, not a change to the underlying clinical story.

What to watch next

Private placement closing, November 4, 2026

Original filing on SEC EDGAR

Lyell Immunopharma private placement adds $80M but dilutes shareholders | LYEL Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.